Vyvanse Manufacturing, Supply & Shortage History

What Is Vyvanse and How Is It Manufactured?

Vyvanse is an amphetamine prodrug: lisdexamfetamine is l-lysine covalently bonded to d-amphetamine. That bond is cleaved by peptidases in red blood cells after oral absorption, releasing active d-amphetamine into systemic circulation. Because conversion depends on erythrocyte enzyme activity rather than gastric pH or intestinal transit, the pharmacokinetic profile is highly consistent across food states and formulations.

The Chemical Synthesis Pathway

Manufacturing lisdexamfetamine requires pharmaceutical-grade d-amphetamine base, which itself is derived from phenylacetone or via reductive amination of phenylpyruvic acid. Both precursor routes involve chemicals listed under DEA Schedule I or II precursor controls. Takeda produces the finished drug substance at facilities subject to FDA Current Good Manufacturing Practice (cGMP) inspections and separate DEA registration.

The coupling step that attaches l-lysine to d-amphetamine requires stereospecific control to maintain the S-configuration of lysine and the dextro-configuration of amphetamine. Any racemic contamination or lysine-coupling failure produces out-of-specification batches. That level of precision means manufacturing scale-up is slow. Adding significant new capacity takes years of facility qualification, not months.

Dosage Forms and Strengths

Vyvanse is available as oral capsules in seven strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. A chewable tablet formulation at the same strengths was approved in 2016, providing an option for patients who cannot swallow capsules. Each formulation contains lisdexamfetamine dimesylate as the salt form, which improves stability relative to the free base.

DEA Quota System: The Regulatory Bottleneck

The DEA sets an Annual Aggregate Production Quota (APQ) for every Schedule II controlled substance under 21 CFR Part 1303. Manufacturers must apply each year, provide projected demand data, and await DEA approval before producing quantities above the prior year's quota. This system was designed to prevent diversion, but its annual cycle creates a structural lag between demand spikes and authorized production.

How the Quota Process Works

1. Manufacturers submit quota applications by May 1 of the preceding year.
2. DEA publishes a proposed aggregate quota in the Federal Register, accepts public comment, and issues a final quota.
3. Individual manufacturers then apply for their share of the aggregate quota.
4. Mid-year supplemental quota requests are possible but require additional DEA review, adding weeks to months of delay.

When ADHD diagnosis rates climb faster than the prior year's demand data predicted, the quota becomes a ceiling that constrains legally manufactured supply even when factory capacity exists to produce more.

Amphetamine APQ Trends

The DEA's aggregate production quota for amphetamine (the controlled substance moiety relevant to lisdexamfetamine) was set at 31.5 metric tons for 2024, up from 22.5 metric tons in 2021. That 40% increase over three years reflects DEA's attempt to catch up with demand, but manufacturers note that quota approval does not automatically translate to available finished-dose product because precursor procurement, facility scheduling, and quality release all add time.

The 2022 to 2025 Shortage: Causes and Timeline

Demand Surge After the COVID-19 Pandemic

Telehealth expansion during the pandemic allowed millions of adults to seek ADHD evaluation for the first time. Prescriptions for amphetamine-based medications rose sharply. According to IQVIA data cited in Congressional testimony, stimulant prescriptions increased approximately 30% between 2020 and 2022. Vyvanse, already the top-selling branded ADHD medication, absorbed a disproportionate share of that growth.

The FDA formally added amphetamine mixed salts and lisdexamfetamine to the drug shortage database in October 2022. FDA's drug shortage database entry for amphetamine products listed the cause as "demand increase" rather than manufacturing disruption, which is clinically significant: the supply chain was intact but simply undersized for the new demand level.

DEA Quota Lag in Practice

A June 2023 letter from the American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association asked the DEA to expedite supplemental quota requests, noting that patients were rationing doses or going without treatment for weeks. The agencies' joint statement read: "The ongoing stimulant shortage is causing measurable harm to patients with ADHD, including worsening academic performance, increased psychiatric hospitalizations, and medication discontinuation."

The timeline of key regulatory events illustrates the lag clearly:

| Date | Event | |------|-------| | Oct 2022 | FDA designates amphetamine products in shortage | | Feb 2023 | DEA issues supplemental quota increase for amphetamine (amount not publicly specified per DEA policy) | | Aug 2023 | First Vyvanse generics approved and enter U.S. Market | | Jan 2024 | FDA reports partial resolution for some amphetamine salts; lisdexamfetamine remains intermittently short | | Jun 2024 | DEA proposes 2025 APQ reflecting further amphetamine increases | | Early 2025 | Spot shortages continue in rural and independent pharmacy markets |

Manufacturing Concentration Risk

Takeda is the sole manufacturer of branded Vyvanse finished-dose product. Before generic entry in August 2023, any single-site manufacturing disruption would have directly reduced national supply with no alternative source. While Takeda operates multiple facilities globally, the U.S. Drug Enforcement Administration requires that controlled-substance manufacturing for U.S. Commercial supply occur at DEA-registered domestic sites or at foreign sites with specific import authorization. That geographic and regulatory concentration amplifies the impact of any batch failure or facility maintenance shutdown.

Post-generic-entry, at least six ANDA holders have received approval to market lisdexamfetamine generics as of mid-2025, including Amneal Pharmaceuticals, Sandoz, and Teva. Each ANDA holder carries its own separate DEA quota allotment, so market entry by multiple manufacturers does expand total authorized supply. Shortages in 2024 and 2025 have been more localized and shorter in duration than the 2022 to 2023 peak.

How Vyvanse Works: Mechanism Relevant to Manufacturing Quality

Understanding mechanism matters for manufacturing because the prodrug design creates quality-control requirements that branded amphetamine salts do not share.

Prodrug Conversion and Its Pharmacokinetic Consequences

After oral ingestion, lisdexamfetamine is absorbed intact from the gastrointestinal tract. Peptidase enzymes on the surface of and within red blood cells cleave the amide bond between lysine and d-amphetamine. The conversion is first-order and saturable, meaning that above a threshold dose, additional lisdexamfetamine does not produce proportionally more peak amphetamine. This saturation mechanism is pharmacologically meaningful for abuse deterrence and produces a Tmax for d-amphetamine of approximately 3.8 hours after lisdexamfetamine ingestion, compared with 1 to 2 hours for immediate-release amphetamine salts.

Clinical Duration and the Wigal Evidence

Wigal et al. (J Atten Disord 2017, N=272 children ages 6 to 12) used a laboratory classroom model to assess ADHD symptom control at hourly intervals. Lisdexamfetamine 30 mg to 70 mg produced statistically significant symptom reduction from 1.5 hours post-dose through 13 hours post-dose relative to placebo, with P<0.001 at most time points. No dose produced meaningful symptom control at 14 hours, confirming the 12 to 13 hour effective window. This extended duration is a direct consequence of the prodrug's slower conversion kinetics compared with equivalent amphetamine salt doses.

Why Prodrug Purity Matters for Efficacy

Any free d-amphetamine present as a manufacturing impurity would shift the pharmacokinetic profile toward a faster Tmax and shorter duration, potentially making the product clinically inferior even if total amphetamine content met label claim. FDA specifications for lisdexamfetamine therefore include limits on unconjugated amphetamine content in finished capsules. Generic manufacturers must demonstrate bioequivalence under 21 CFR 320 and meet the same impurity specifications, which adds a layer of analytical complexity that can slow batch-release timelines.

Generic Entry in 2023: Did It Solve the Shortage?

What Happened at Generic Launch

Teva, Amneal, and Sandoz launched authorized generics in August 2023 when Takeda's compound patent on lisdexamfetamine dimesylate expired. The authorized generics are manufactured using Takeda's own drug substance, so they do not require separate drug substance scale-up. Independent ANDA products using independently synthesized drug substance require more time to reach market scale.

Patient-level access improved in urban pharmacy markets relatively quickly. However, rural independent pharmacies, which order through regional wholesalers rather than direct manufacturer contracts, continued to report lisdexamfetamine stockouts through 2024.

Price Impact of Generic Entry

The entry of generic lisdexamfetamine reduced cash-pay prices from approximately $380 per month for brand Vyvanse to $70 to $120 per month for generics by mid-2024, based on GoodRx pricing data. For patients without adequate pharmacy benefit coverage, this was the most clinically meaningful change of the entire shortage period.

Remaining Supply Vulnerabilities

Generic market entry diversifies supply but does not eliminate it as a risk factor. Each generic manufacturer still operates under a DEA quota ceiling. If aggregate demand continues rising faster than DEA quota adjustments, even a six-manufacturer market could face simultaneous supply pressure. The FDA's shortage prevention framework, updated in 2023, requires manufacturers to notify FDA at least six months before an anticipated supply interruption, but the framework does not apply to demand-driven shortages where no single manufacturer is reducing output.

What Prescribers Should Do During a Vyvanse Shortage

Confirming a Shortage Before Switching

Before switching a stable patient off lisdexamfetamine, confirm that the shortage is real and local rather than system-wide. The FDA drug shortage database is updated weekly. Checking the current status takes less than two minutes and should precede any prescribing change.

Pharmacologic Alternatives

If lisdexamfetamine is unavailable, the closest therapeutic alternatives by mechanism are:

• Mixed amphetamine salts extended-release (Adderall XR or generic): similar active moiety, different delivery system, shorter effective window of approximately 8 to 10 hours.
• Dextroamphetamine extended-release (Dexedrine Spansule): pure d-amphetamine, roughly 8-hour duration.
• Methylphenidate extended-release products (Concerta, Ritalin LA, generics): different mechanism via dopamine/norepinephrine reuptake inhibition rather than release, may require dose titration from scratch.

The American Academy of Pediatrics ADHD clinical practice guideline notes that switching between stimulant classes is reasonable when supply of a preferred agent is unavailable, but recommends starting at a lower dose and titrating because cross-class equivalence ratios are approximate.

Regulatory Recourse for Prescribers

Prescribers experiencing systematic shortages can file a shortage report directly with FDA MedWatch or through the ASHP shortage reporting system. Aggregate reports from prescribers contribute to DEA supplemental quota requests. The American Society of Health-System Pharmacists maintains a shortage resource page that tracks real-time status.

Regulatory History and Patent Timeline

Vyvanse received initial FDA approval on February 23, 2007, for ADHD in children ages 6 to 12. The approval was based on a double-blind, placebo-controlled trial showing statistically significant improvement on the ADHD Rating Scale-IV. Approval was subsequently extended to adolescents in 2008 and adults in 2008, and then to moderate-to-severe binge eating disorder in adults in January 2015.

Takeda held multiple patents covering the lisdexamfetamine molecule, its dimesylate salt form, methods of treatment, and specific capsule formulations. The compound patent expired in August 2023. Pediatric exclusivity, which adds six months to the patent term for qualifying pediatric studies, extended brand exclusivity on certain indications through early 2024.

FDA's Orange Book listing for lisdexamfetamine dimesylate shows 22 ANDA applications filed as of 2024, of which 11 had received approval by mid-2025. Not all approved ANDAs represent products actively marketed; some holders hold approvals for strategic or licensing purposes without commercial launch.

Binge Eating Disorder Indication: A Supply Complication

The January 2015 approval for moderate-to-severe binge eating disorder expanded the eligible patient population for Vyvanse by approximately 2.8 million adults based on prevalence data from the National Comorbidity Survey Replication. Because binge eating disorder affects a predominantly adult female population while ADHD prescribing had historically skewed toward pediatric and adult male patients, BED approval opened Vyvanse to prescribers and patients in clinical settings that had not previously been major lisdexamfetamine consumers.

This expansion, combined with growing recognition of ADHD in adult women, created compounding demand growth. DEA quota requests filed before 2020 did not anticipate either the BED expansion's full commercial uptake or the telehealth-driven ADHD diagnosis surge. The result was that by 2022, demand had structurally outpaced quota allocations that had been calculated from pre-2015 utilization trajectories.

International Supply and Regulatory Divergence

Lisdexamfetamine is not universally available internationally. In Canada, Health Canada approved Vyvanse for ADHD in 2009 and for BED in 2018. The European Medicines Agency approved Elvanse (the EU brand name) for ADHD in adults in 2013. Australia's Therapeutic Goods Administration approved lisdexamfetamine in 2015.

Each jurisdiction maintains its own controlled-substance quota and import authorization system. U.S. Patients who travel internationally cannot reliably obtain their lisdexamfetamine prescription abroad because Schedule II import for personal use is prohibited under U.S. Federal law without a DEA import permit, and most destination countries will not dispense Schedule II-equivalent controlled substances on a foreign prescription.

The International Narcotics Control Board (INCB) annual report tracks global amphetamine-type stimulant production and demand annually. The 2023 INCB report noted a 25% increase in lisdexamfetamine defined daily doses (DDDs) consumed globally between 2019 and 2022, reflecting demand growth well beyond U.S. Borders.

What Patients Should Know

Patients facing a lisdexamfetamine shortage have four practical options. First, call multiple pharmacies directly before concluding that no supply exists in a given area. Chain and independent pharmacies order from different wholesalers and may have different stock levels. Second, ask the prescriber whether a 90-day supply can be requested at the next refill if state law permits, reducing monthly restocking risk. Third, ask about generic lisdexamfetamine specifically by name when calling pharmacies, because some pharmacies stock generic but not brand, or vice versa. Fourth, if a therapeutic switch becomes necessary, request a written protocol from the prescriber specifying the starting dose and titration schedule for the alternative medication.

The DEA prohibits early refills of Schedule II prescriptions except in specific circumstances. Patients should not expect that a shortage creates an exception to that rule. Some states have enacted emergency shortage dispensing provisions, but these vary by jurisdiction and do not uniformly apply to controlled substances.

The FDA's consumer guidance on drug shortages states: "FDA works closely with manufacturers to help prevent shortages and to help mitigate shortages that do occur." Patients can check the FDA shortage database themselves at accessdata.fda.gov/scripts/drugshortages.